Cash, cash equivalents, restricted cash and marketable securities.

No definition available.

Name:	nerv_CashCashEquivalentsRestrictedCashAndMarketableSecurities
Namespace Prefix:	nerv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Gross proceeds, before deducting placement agent fees and other expenses.

+ References

No definition available.

+ Details

Name:	nerv_GrossProceedsBeforeDeductingPlacementAgentFeesAndOtherExpenses
Namespace Prefix:	nerv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Maximum potential proceeds from exercise of warrants.

+ References

No definition available.

+ Details

Name:	nerv_MaximumPotentialProceedsFromExerciseOfWarrants
Namespace Prefix:	nerv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Nature of operations and liquidity.

+ References

No definition available.

+ Details

Name:	nerv_NatureOfOperationsAndLiquidityLineItems
Namespace Prefix:	nerv_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential future milestone payments.

+ References

No definition available.

+ Details

Name:	nerv_PotentialFutureMilestonePayments
Namespace Prefix:	nerv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Upfront payment.

+ References

No definition available.

+ Details

Name:	nerv_UpfrontPayment
Namespace Prefix:	nerv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of warrants or rights outstanding.

+ References

No definition available.

+ Details

Name:	us-gaap_ClassOfWarrantOrRightOutstanding
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_NetCashProvidedByUsedInOperatingActivities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.

+ References

+ Details

Name:	us-gaap_PreferredStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(17))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:	us-gaap_RetainedEarningsAccumulatedDeficit
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_StatementClassOfStockAxis=nerv_SeriesAConvertiblePreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=nerv_TrancheAWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=nerv_TrancheBWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=nerv_SeltorexantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nerv_RoyaltyPharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

NATURE OF OPERATIONS AND LIQUIDITY - Additional Information (Details) - USD ($)			1 Months Ended	3 Months Ended
	Oct. 23, 2025	Jan. 19, 2021	Jan. 31, 2021	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025
Nature Of Operations And Liquidity [Line Items]
Accumulated deficit				$ 814,204,124		$ 688,799,740
Net cash used in operating activities				5,427,064	$ 4,071,960
Cash, cash equivalents, restricted cash and marketable securities				$ 78,200,000
Preferred stock, shares issued				0		0
Series A Convertible Preferred Stock \| Private Placement
Nature Of Operations And Liquidity [Line Items]
Proceeds from exchange of preferred stock	$ 80,000,000
Preferred stock, shares issued	80,000
Tranche A Warrants \| Private Placement
Nature Of Operations And Liquidity [Line Items]
Warrants exercised	80,000
Tranche B Warrants \| Private Placement
Nature Of Operations And Liquidity [Line Items]
Potential proceeds from excersie of warrants	$ 40,000,000
Warrants exercised	40,000
Maximum \| Private Placement
Nature Of Operations And Liquidity [Line Items]
Gross proceeds before deducting placement agent fees and other expenses	$ 200,000,000
Seltorexant
Nature Of Operations And Liquidity [Line Items]
Additional milestone payments			$ 80,000,000
Potential Future Milestone Payments			80,000,000
Seltorexant \| Royalty Pharma
Nature Of Operations And Liquidity [Line Items]
Up front payment		$ 60,000,000	60,000,000
Additional milestone payments			95,000,000
Potential Future Milestone Payments			$ 95,000,000